INB03, also known as XPro1595 is a novel, second-generation TNF inhibitor that works by a Dominant Negative technology. INB03 is a PEGylated protein therapeutic that is administered as a once-weekly subcutaneous injection similar to an insulin shot. INB03 is not an antibody. INB03 neutralizes soluble TNF without affecting any other parts of TNF biology, allowing for more precise targeting. INB03 is differentiated from first-generation, approved TNF inhibitors that are used to treat autoimmune disorders such as rheumatoid arthritis. These first-generation TNF inhibitors are contra-indicated in patients with cancer because they cause immunosuppression, a side effect that could worsen the cancer.

свернуть